Pathogen Inactivation

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 801-810

  Solheim, Bjarte G ^a   Seghatchian, Jerard ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Molecular Haemostasis and Thrombosis Laboratory   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991490033     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch51     Document Type: Chapter

References (77)

1. McDonald C, Roy A, Mahajan P, et al. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion. Vox Sang 2004;86:178-82.
2. Solheim BG, Cid J, Osselaer JC. Pathogen reduction technologies. In: Lozano M, Contreras M, Blajchman M, eds. Global perspectives in transfusion medicine. Bethesda, MD: AABB Press, 2006:103-48.
3. Rasonglès P, Isola H, Kientz D, et al. Rapid implementation of photochemical pathogen inactivation (INTERCEPT) for preparation of platelet components during an epidemic of chikungunya virus (abstract). Vox Sang 2006;91(Suppl 3):32.
4. Olsen H, Andersen A, Nordbo A, et al. Pharmaceutical-grade albumin: Impaired drug-binding capacity in vitro. BMC Clin Pharmacol 2004;4:4.
5. Epstein JS, Vossal JG. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003;43:1347-50.
6. Pelletier JPR, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006;19:205-42.
7. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma. A virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-33.
8. Hellstern P, Sachse H, Schwinn H, Oberefrank K. Manufacture and in-vitro characterization of a solvent/detergent-treated plasma. Vox Sang 1992;63:178-85.
9. Horowitz B, Lazo A, Grossberg H, et al. Virus inactivation by sol- vent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998;74(Suppl 1):203-6.
10. Roberts P. Resistance of vaccinia virus to inactivation by solvent/ detergent treatment of blood products. Biologicals 2000;28:29-32.
11. Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/ detergent-treated plasma. Transfusion 2000;40:84-90.
12. Rollag H, Solheim BG, Svennevig JL. Viral safety of blood derivatives by immune neutralization. Vox Sang 1998;74(Suppl 1):213-17.
13. 2-antiplasmin (SERPINF2) activity in solvent/ detergent-treated plasma. Biologicals 2007;35:349-53.
14. Burnouf T, Goubran HA, Radosevich M, El-Ekiaby M. Preparation and viral inactivation of cryoprecipitate in blood banks in resource- limited countries. ISBT Science Series 2007;2:121-8.
15. Burnouf T, Goubran HA, Radosevich M, et al. A process for solvent/ detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 2006;46:2100-8.
16. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008;39:75-82.
17. Hellstern P. Solvent/detergent-treated plasma: Composition, efficacy, and safety. Curr Opin Hematol 2004;11:346-50.
18. Runkel S, Haubelt H, Hitzler W, Hellstern P. The quality of plasma collected by automated apheresis and of recovered plasma from leu- kodepleted whole blood. Transfusion 2005;45:427-32.
19. Solheim BG, Hellstern P. Composition, efficacy, and safety of S/D- treated plasma (letter). Transfusion 2003;43:1176-8.
20. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al. Are quality differences responsible for different adverse reactions reported for SD-plasma for USA and Europe? Transfus Med 2006;16:266-75.
21. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: An overview. Transfus Apher Sci 2006;35:83-90.
22. Hellstern P. Fresh-frozen plasma, pathogen-reduced single donor plasma or biopharmaceutical plasma? Transfus Apher Sci 2008;39:69-74.
23. Matsuda M, Wakabayashi K, Aoki N, Morioka Y. Alpha 2-plasmin inhibitor is among acute phase reactants. Thromb Res 1980;17:527-32.
24. Solheim BG, Bergan A, Brosstad F, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus- inactivated plasma (ESDEP/Octaplas) (letter). Anesth Analg 2003;96:1230-1.
25. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-85.
26. Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic pupura. Vox Sang 2007;93:153-8.
27. Solheim BG. Plasma induced TRALI is avoided with solvent/ detergent-treated plasma (abstract). Transfusion Alternatives in Transfusion Medicine 2005;7(Suppl):57.
28. Bux J. Transfusion-related acute lung injury (TRALI): A serious adverse event of blood transfusion. Vox Sang 2005;89:1-10.
29. Chapanduka ZC, Fernandez-Costa FJ, Rochat C, et al. Comparative safety and efficacy of Bioplasma FDP versus single-donor fresh- dried plasma in cardiopulmonary bypass patients (letter). S Afr Med J 2002;92:356-7.
30. Solheim BG. Universal pathogen-reduced plasma in elective open- heart surgery and liver resection. Clin Med Res 2006;4:209-17.
31. Tollofsrud S, Noddeland H, Svennevig JL, et al. Universal fresh frozen plasma (Uniplas): A safe product in open-heart surgery. Intensive Care Med 2003;29:1736-43.
32. Solheim BG, Granov DA, Juralev VA, et al. Universal fresh-frozen plasma (Uniplas): An exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005;89:19-26.
33. Clifton CE. Photodynamic action of certain dyes on the inactivation of staphylococcus bacteriophage. Proc Soc Exp Biol Med 1931;28:745-6.
34. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002;16:61-6.
35. Krailadsiri P, Seghatchian J, Macgregor I, et al. The effects of leu- kodepletion on the generation and removal of microvesicles and prion protein in blood components. Transfusion 2006;45:407-17.
36. Abe H, Yamada-Ohnishi Y, Hirayama J, et al. Elimination of both cell-free and cell-associated HIV infectivity in plasma by a fil- tration/methylene blue photoinactivation system. Transfusion 2000;40:1081-7.
37. Seghatchian J, Krailadsiri P. What's happening? The quality of methylene blue treated FFP and cryo. Transfus Apher Sci 2001;25:227-31.
38. Mohr H, Lambrecht B, Seltz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995;24:73-85.
39. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: What is its contribution to blood safety? Transfusion 2003;43:1322-9.
40. Wieding JU, Rathgeber J, Zenker D. Prospective, randomized and controlled study on solvent/detergent versus methylene blue/light virus inactivated plasma (abstract). Transfusion 1999;39(Suppl):23S.
41. Politis C, Kavallierou L, Hantziara S, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007;92:319-26.
42. Pock K, Heger A, Janisch S, et al. Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent- treated plasma (Octaplas) and a development product (Uniplas). Transfus Apher Sci 2007;37:223-31.
43. Depasse F, Sensebe L, Seghatchian J, et al. The influence of methylene blue light treatment and methylene blue removal fillter on fibrinogen activity states and fibrin polymerization indices. Transfus Apher Sci 2005;33:63-9.
44. Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51.
45. Skripchenko A, Wagner SJ, Thompson-Montgomery D, Awatefe H. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties. Transfusion 2006;46:213-19.
46. Singh Y, Sawyer L, Pinkoski L, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006;46:1168-77.
47. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT blood system. Vox Sang 2003;85:171-82.
48. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: Transfusion of patients with congenital coagulation deficiencies. Transfusion 2005;45:1362-72.
49. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302-7.
50. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006;107:3753-60.
51. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh frozen plasma prepared with amotosalen and UV light compared to untreated fresh frozen plasma in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704.
52. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
53. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV light based pathogen reduction: Extent and consequence of DNA damage at molecular level. Photochem Photobiol 2004;75:561-4.
54. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
55. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79:206-14.
56. Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O. Cytokine accumulation in photochemical treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006;46:800-10.
57. Seghatchian J, de Sousa G. Pathogen-reduction systems for blood components: The current and future trends. Transfus Apher Sci 2006;35:189-96.
58. Apelseth TO, Bruserud O, Wentzel-Larsen T, et al. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single donor platelet concentrates during long-term storage. Transfusion 2007;47:653-65.
59. van Rhenen DJ, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003;101:2426-33.
60. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT trial. Blood 2004;104:1534-41.
61. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen- reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45:911-19.
62. Li J, Lockerbie O, de Korte D, et al. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology. Transfusion 2005;45:920-6.
63. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
64. Cook D, Wollowitz D, inventors. Method for inactivating pathogens in red cell compositions using quinacrine mustard. US patent 5691132. November 25, 1997.
65. Creech HJ, O'Connell AP. Immunochemistry of conjugates prepared from serum albumins and acridine nitrogen mustards (ICR mutagens). Cancer Res 1981;41:3844-51.
66. Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang 2000;78(Suppl 2):205-10.
67. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: A Phase III clinical trial in cardiac surgery patients. Transfusion 2005;45:1739-49.
68. Stassinopoulos A, Castro GM, Schott MA. A modified S-303 pathogen inactivation process eliminates immunoreactivity of S-303 RBC detected in pivotal clinical trials (abstract). Haematologica 2005;90:774.
69. Preuss T, Kamstrup S, Kyvsgaard NC, et al. Comparison of two different methods for inactivation of viruses in serum. Clin Diagn Lab Immunol 1997;4:504-8.
70. Käsermann F, Wyss K, Kempf C. Virus inactivation and protein modifications by ethyleneimines. Antiviral Res 2001;52:33-41.
71. Chapman J, Moore K, Butterworth BE. Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion 2003;43:1386-93.
72. Wagner SJ, Skripchenko A, Cincotta L, et al. Use of a flexible thi- opyrulium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties. Transfusion 2005;45:752-60.
73. Svae TE, Neisser-Svae A, Bailey A, et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apher Sci 2008;39:59-67.
74. Achour A. Phenothiazines and prion diseases: A potential mechanism of action towards oxidative stress. Int J Antimicrob Agents 2002;20:305-6.
75. Klein HG. Pathogen inactivation technology: Cleansing the blood supply. J Intern Med 2005;257:224-37.
76. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: Making decisions about new technologies-preliminary report of a consensus conference. Vox Sang 2007;93:179-82.
77. Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in health care decision-making. Pharmaeconomics 1998;13:277-88.